Stocks Health care ADXN
NASDAQ · Health careAddex Therapeutics Ltd. (ADXN)
Addex Therapeutics Ltd. reported revenue of CHF 404.1K in fiscal 2024, down 74.9% from a year earlier. Net income was CHF 7.1M, a net margin of 1,746.0%. In fiscal 2024 capital spending exceeded operating cash flow by CHF 5.4M. At December 31, 2024 it held CHF 3.3M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on May 15, 2026.
What Addex Therapeutics Ltd. does
Addex Therapeutics Ltd. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ADXN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2024 | CHF 404.1K | CHF 7.1M | CHF 0.07 | -CHF 5.4M |
| 2023 | CHF 1.6M | -CHF 10.6M | -CHF 0.14 | -CHF 8M |
| 2022 | CHF 1.4M | -CHF 20.8M | -CHF 0.46 | -CHF 16.4M |
| 2021 | CHF 2.9M | -CHF 15.4M | -CHF 0.45 | -CHF 14.7M |
| 2020 | CHF 3.6M | -CHF 12.9M | -CHF 0.48 | -CHF 12.2M |
| 2019 | CHF 2.8M | -CHF 14.8M | -CHF 0.56 | -CHF 9.5M |
Latest SEC filings
What Addex Therapeutics Ltd. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 25, 2026
- September 4, 2026Activist stake changed SCHEDULE 13D/A
- August 27, 2026Activist stake changed SCHEDULE 13D/A
- August 26, 2026
- July 8, 2026
- June 30, 2026
- June 25, 2026
- June 5, 2026
- May 15, 2026Annual report (foreign issuer) 20-F · period to December 31, 2025
- April 30, 2026Form NT 20-F filing NT 20-F
Insider trades
What the people running Addex Therapeutics Ltd. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 14 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 2, 2026 | Dyer Timothy MarkCHIEF EXECUTIVE OFFICER, Director | Other change | 16,413,787 | - |
| September 2, 2026 | Dyer Timothy MarkCHIEF EXECUTIVE OFFICER, Director | Received as pay | 16,413,787 | - |
| September 2, 2026 | Hill Raymond GeorgeDirector | Other change | 1,365,532 | - |
| September 2, 2026 | Hill Raymond GeorgeDirector | Received as pay | 1,365,532 | - |
| September 2, 2026 | Lawton Vincent MichaelDirector | Other change | 2,507,487 | - |
| September 2, 2026 | Lawton Vincent MichaelDirector | Received as pay | 2,507,487 | - |
| September 2, 2026 | Manke IsaacDirector | Other change | 219,561 | - |
| September 2, 2026 | Manke IsaacDirector | Received as pay | 219,561 | - |
| September 2, 2026 | Mills RogerCHIEF MEDICAL OFFICER, Director | Other change | 392,837 | - |
| September 2, 2026 | Mills RogerCHIEF MEDICAL OFFICER, Director | Received as pay | 392,837 | - |
| September 2, 2026 | Nunn Jason RaleighDirector | Other change | 219,561 | - |
| September 2, 2026 | Nunn Jason RaleighDirector | Received as pay | 219,561 | - |
| September 2, 2026 | Kalinichev MikhailHEAD OF TRANSLATIONAL SCIENCE | Other change | 306,765 | - |
| September 2, 2026 | Kalinichev MikhailHEAD OF TRANSLATIONAL SCIENCE | Received as pay | 306,765 | - |
Who owns ADXN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Timothy Mark Dyer13D, may seek influence | 9.01% | September 4, 2026 |
Largest institutional holders
Insiders
7 insiders reported holding 22,254,361 shares in total, about $81.2M at the last price.
| Holder | Shares |
|---|---|
| Dyer Timothy MarkCHIEF EXECUTIVE OFFICER, Director | 16,848,979 |
| Lawton Vincent MichaelDirector | 2,507,987 |
| Hill Raymond GeorgeDirector | 1,365,532 |
| Mills RogerCHIEF MEDICAL OFFICER, Director | 785,976 |
| Kalinichev MikhailHEAD OF TRANSLATIONAL SCIENCE | 306,765 |
| Nunn Jason RaleighDirector | 219,561 |
| Manke IsaacDirector | 219,561 |
Questions about ADXN
What does Addex Therapeutics Ltd. do?
Addex Therapeutics Ltd. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ADXN.
Is Addex Therapeutics Ltd. profitable?
Yes. In fiscal 2024 it reported net income of CHF 7.1M on revenue of CHF 404.1K, a net margin of 1,746.0%.
How much revenue does Addex Therapeutics Ltd. make?
In fiscal 2024 Addex Therapeutics Ltd. reported revenue of CHF 404.1K. That is 74.9% less than a year earlier.
When did Addex Therapeutics Ltd. last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on May 15, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from September 25, 2026.
Similar companies
Compare ADXN with
Follow ADXN
Get an email when Addex Therapeutics Ltd. files with the SEC: results, executive changes, material agreements and annual reports.
Follow ADXN: get an email when it filesWhere the numbers come from
Financial figures are the values Addex Therapeutics Ltd. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.